GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » Stock Based Compensation

LTR Pharma (ASX:LTP) Stock Based Compensation : A$0.00 Mil (TTM As of Jun. 2023)


View and export this data going back to 2023. Start your Free Trial

What is LTR Pharma Stock Based Compensation?

LTR Pharma's Stock Based Compensation for the six months ended in Jun. 2023 was A$0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2023 was A$0.00 Mil.


LTR Pharma Stock Based Compensation Historical Data

The historical data trend for LTR Pharma's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LTR Pharma Stock Based Compensation Chart

LTR Pharma Annual Data
Trend Jun21 Jun22 Jun23
Stock Based Compensation
- - -

LTR Pharma Semi-Annual Data
Jun21 Jun22 Jun23
Stock Based Compensation - - -

LTR Pharma Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2023 was A$0.00 Mil.


LTR Pharma Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of LTR Pharma's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


LTR Pharma (ASX:LTP) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
9A/204 Alice Street, Brisbane, QLD, AUS, 4000
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on market.

LTR Pharma (ASX:LTP) Headlines

No Headlines